Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 146-147

  Bonora, Stefano ^a,c   Lanzafame, Massimiliano ^b   D'Avolio, Antonio ^a   Trentini, Laura ^a   Lattuada, Emanuela ^b   Concia, Ercole ^b   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; VITAMIN K GROUP; WARFARIN; ZIDOVUDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VENA CAVA FILTER;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; WARFARIN;

EID: 39349087177     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524086     Document Type: Letter

References (7)

1. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44:1227-46.
2. Dionisio D, Mininni S, Bartolozzi D, Esperti F, Vivarelli A, Leoncini F. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001; 15:277-8.
3. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40:893-905.
4. Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM. A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis 2005; 41:e15-8.
5. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853-63.
6. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32:194-209.
7. Yeh R, Gaver V, Park J, et al. Lopinavir/ritonavir induces CYP2C9 and 2C19 activity as measured by warfarin and omeprazole biomarkers in healthy human volunteers [abstract 4.1]. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy (Rome). The Netherlands: Virology Education, 2004; 10.